RecGBM are frequently treated with bevacizumab, an anti-angiogenic drug that targets the VEGF-VEGFR axis with the aim of disrupting tumor angiogenesis; however, survival benefits with this monotherapy are negligible [29]. This evidence concerns the gene KDR and neoplasm.